← Leaderboards
Steven Fletcher
University Of Maryland Baltimore
$1,266,142
Attributed
$3,611,414
Total exposure
5
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,212,061 · 3
FDA$1,399,353 · 2
By mechanism
R01$1,538,292 · 1
U01$1,399,353 · 2
R21$393,647 · 1
T32$280,122 · 1
Top collaborators
- France Carrier4 shared
- Jace W Jones4 shared
- David Joseph Weber4 shared
- Robert G Brinson2 shared
- Curt I Civin2 shared
- Michael P Cummings2 shared
- Hongbing Wang2 shared
- Aaron T Smith1 shared
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- France Carrier$2,949,818
- David Joseph Weber$22,294,951
- Anthony J. Kim$3,391,136
- Charles D Howell$4,304,760
- Mitchell Bradley Moyer$38,306
Others in their field
Other Emerging Leaders on “Untranslated Regions”
- Yin Shen · University Of California, San Francisco$9,733,134
- Pradeep Natarajan · Massachusetts General Hospital$4,332,359
- Joseph Mauro Calabrese · Univ Of North Carolina Chapel Hill$4,145,329
- Paul Stefan De Vries · University Of Texas Hlth Sci Ctr Houston$3,893,580
- Ayellet Vered Segre · Massachusetts Eye And Ear Infirmary$3,794,243
- Chongyuan Luo · University Of California Los Angeles$3,713,845
Research focus
Untranslated RegionsResponseAnalogProteinsApoptosisSolid NeoplasmDown-RegulationIn VivoModificationPharmaceutical PreparationsBiologicalResistanceSmall MoleculeCellsXenograft ModelDesignDrug DesignIn VitroLeadMalignant NeoplasmsOverexpressionBindingXenograft ProcedureInhibitor
Grant awards (11)
First in Class Small molecules to simultaneously inhibit protein translation and an immune checkpoint in cancers$639,330
R01 · FY2025 · CA
Comprehensive assessment of the diastereomer composition of LEQVIO (Inclisiran) to determine how chemical synthesis impacts biological activity$499,887
U01 · FY2025 · FD
Graduate Training at The Chemistry Biology Interface$280,122
T32 · FY2025 · GM
First in Class Small molecules to simultaneously inhibit protein translation and an immune checkpoint in cancers$184,185
R01 · FY2025 · CA
First in Class Small molecules to simultaneously inhibit protein translation and an immune checkpoint in cancers$639,330
R01 · FY2024 · CA
Comprehensive assessment of the diastereomer composition of LEQVIO (Inclisiran) to determine how chemical synthesis impacts biological activity$299,975
U01 · FY2024 · FD
Investigating the hnRNPA18-HIF-1a axis in solid tumors$75,447
R01 · FY2024 · CA
Multidimensional analytical and computational approach to determine diastereomer compositions in oligonucleotide drug products$299,555
U01 · FY2023 · FD
Multidimensional analytical and computational approach to determine diastereomer compositions in oligonucleotide drug products$299,936
U01 · FY2022 · FD
Synthetic Strategies to Restore the Efficacy of Venetoclax in Acute Myeloid Leukemia$176,961
R21 · FY2022 · CA · contact PI
Synthetic Strategies to Restore the Efficacy of Venetoclax in Acute Myeloid Leukemia$216,686
R21 · FY2021 · CA · contact PI